Biden-Xi Bali Meet Reopens US-China Cooperation, Looks Positive For Health Players
Rare Positive Signal Amid Wider Decoupling
Executive Summary
A meeting between the heads of the world's two largest economies potentially opens the door for health cooperation, a rare positive sign amid worsening economic decoupling, accelerating diversification away from China and the need for multinationals to modify localization strategy.
You may also be interested in...
US Consumer Health Industry In 2023: With Supply Chain Concerns Constant, Challenges Loom Larger
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight begins reporting from those talks with outlook for supply chain nd production disruptions and prevalence of COVID-19 and other widespread viruses.
China’s Regulator Has New Head But Will He Advance Further Reforms?
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Hua Medicine's Chen On Product Launch, Bayer Partnership And Reimbursement
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.